Cargando…

Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review)

Latent tuberculosis infection (LTBI) represents a major challenge to curing TB disease. Current guidelines for LTBI management include only three older drugs and their combinations—isoniazid and rifamycins (rifampicin and rifapentine). These available control strategies have little impact on latent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Egorova, Anna, Salina, Elena G., Makarov, Vadim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707483/ https://www.ncbi.nlm.nih.gov/pubmed/34948114 http://dx.doi.org/10.3390/ijms222413317

Ejemplares similares

Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger
por: Salina, Elena G., et al.
Publicado: (2022)

Dispirotripiperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design (mini-review)
por: Egorova, Anna, et al.
Publicado: (2021)

Mycobacterium tuberculosis Infection: Control and Treatment
por: Salina, Elena G.
Publicado: (2023)

Prevalence of latent Mycobacterium tuberculosis infection in prisoners
por: de Navarro, Pedro Daibert, et al.
Publicado: (2016)

Behçet’s disease with latent Mycobacterium tuberculosis infection
por: Shen, Yan, et al.
Publicado: (2020)

Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection
por: Mayito, Jonathan, et al.
Publicado: (2019)

Cytokine Biosignature of Active and Latent Mycobacterium Tuberculosis Infection in Children
por: Druszczynska, Magdalena, et al.
Publicado: (2021)

Pathogenesis, Immunology, and Diagnosis of Latent Mycobacterium tuberculosis Infection
por: Ahmad, Suhail
Publicado: (2011)

Diagnosis for Latent Tuberculosis Infection: New Alternatives
por: Carranza, Claudia, et al.
Publicado: (2020)

Small Noncoding RNAs and Their Role in the Pathogenesis of Mycobacterium tuberculosis Infection
por: Ostrik, Albina A., et al.
Publicado: (2021)

An Overview of Genetic Information of Latent Mycobacterium tuberculosis
por: Hamidieh, Faezeh, et al.
Publicado: (2021)

CanB, a Druggable Cellular Target in Mycobacterium tuberculosis
por: Degiacomi, Giulia, et al.
Publicado: (2023)

Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection
por: Schuck, Sebastian D., et al.
Publicado: (2009)

Prevalence of latent Mycobacterium tuberculosis infection in renal transplant recipients
por: Maciel, Mônica Maria Moreira Delgado, et al.
Publicado: (2018)

Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation
por: Silva, Jose Tiago, et al.
Publicado: (2019)

Stratification of Latent Mycobacterium tuberculosis Infection by Cellular Immune Profiling
por: Halliday, Alice, et al.
Publicado: (2017)

Serum antibody profiles in individuals with latent Mycobacterium tuberculosis infection
por: Maekura, Ryoji, et al.
Publicado: (2019)

Prophylactic Use of Ganoderma lucidum Extract May Inhibit Mycobacterium tuberculosis Replication in a New Mouse Model of Spontaneous Latent Tuberculosis Infection
por: Zhan, Lingjun, et al.
Publicado: (2016)

Mycobacterium tuberculosis Small RNA MTS1338 Confers Pathogenic Properties to Non-Pathogenic Mycobacterium smegmatis
por: Bychenko, Oksana, et al.
Publicado: (2021)

Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis
por: Glenn, Sarah M., et al.
Publicado: (2022)

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries
por: Getahun, Haileyesus, et al.
Publicado: (2015)

Mycobacterium tuberculosis Secreted Proteins As Potential Biomarkers for the Diagnosis of Active Tuberculosis and Latent Tuberculosis Infection
por: Zhang, Caiqin, et al.
Publicado: (2014)

A New Benzothiazolthiazolidine Derivative, 11726172, Is Active In Vitro, In Vivo, and against Nonreplicating Cells of Mycobacterium tuberculosis
por: Salina, Elena G., et al.
Publicado: (2022)

Preventive effects of Mycobacterium tuberculosis DNA vaccines on the mouse model with latent tuberculosis infection
por: Liang, Yan, et al.
Publicado: (2023)

Targeted metabolomics analysis of serum and Mycobacterium tuberculosis antigen-stimulated blood cultures of pediatric patients with active and latent tuberculosis
por: Magdalena, Druszczynska, et al.
Publicado: (2022)

ORFeome-based identification of biomarkers for serodiagnosis of Mycobacterium tuberculosis latent infection
por: Zhou, Fangbin, et al.
Publicado: (2017)

Mycobacterium tuberculosis progresses through two phases of latent infection in humans
por: Colangeli, Roberto, et al.
Publicado: (2020)

Differential levels of anti-Mycobacterium tuberculosis-specific IgAs in saliva of household contacts with latent tuberculosis infection
por: Ruiz-Tagle, Cinthya, et al.
Publicado: (2023)

Resuscitation of Dormant “Non-culturable” Mycobacterium tuberculosis Is Characterized by Immediate Transcriptional Burst
por: Salina, Elena G., et al.
Publicado: (2019)

Small Molecules—Prospective Novel HCMV Inhibitors
por: Bogner, Elke, et al.
Publicado: (2021)

A class of hydrazones are active against non-replicating Mycobacterium tuberculosis
por: Bonnett, Shilah A., et al.
Publicado: (2018)

Transcription of Genes Involved in Sulfolipid and Polyacyltrehalose Biosynthesis of Mycobacterium tuberculosis in Experimental Latent Tuberculosis Infection
por: Rodríguez, Jimmy E., et al.
Publicado: (2013)

Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection
por: Mehaffy, Carolina, et al.
Publicado: (2020)

Serum proteomic analysis of Mycobacterium tuberculosis antigens for discriminating active tuberculosis from latent infection
por: Peng, Zhangli, et al.
Publicado: (2020)

Dormant non-culturable Mycobacterium tuberculosis retains stable low-abundant mRNA
por: Ignatov, Dmitriy V., et al.
Publicado: (2015)

Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
por: Campos, Débora Leite, et al.
Publicado: (2022)

Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro
por: Larson, Erica C., et al.
Publicado: (2017)

Potassium availability triggers Mycobacterium tuberculosis transition to, and resuscitation from, non-culturable (dormant) states
por: Salina, Elena G., et al.
Publicado: (2014)

Analysis of latent tuberculosis and mycobacterium avium infection data using mixture models
por: Villate, José I, et al.
Publicado: (2006)

Co-infection with Drug-Susceptible and Reactivated Latent Multidrug-Resistant Mycobacterium tuberculosis
por: Pérez-Lago, Laura, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0v4e5kkgjeegoert2qmd8kfdt9